PriceTargets.com logo

Evoke Pharma - EVOK Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.07 As of 12/20/2024 06:45 PM ET
▼ -0.42 (-7.65%)

This chart shows the closing price for EVOK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evoke Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVOK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Evoke Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.07.

This chart shows the closing price for EVOK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Evoke Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/10/2020HC WainwrightReiterated RatingBuy$1,440.00
7/17/2020HC WainwrightReiterated RatingBuy$1,440.00
6/22/2020HC WainwrightUpgradeNeutral ➝ Buy$1,440.00
5/21/2020HC WainwrightReiterated RatingHold
1/28/2020HC WainwrightReiterated RatingHold
(Data available from 12/22/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Evoke Pharma logo
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Read More

Today's Range

Now: $5.07
Low: $4.81
High: $5.38

50 Day Range

MA: $4.95
Low: $4.08
High: $7.08

52 Week Range

Now: $5.07
Low: $3.54
High: $14.16

Volume

53,206 shs

Average Volume

119,953 shs

Market Capitalization

$7.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Evoke Pharma?

The following Wall Street sell-side analysts have issued research reports on Evoke Pharma in the last year: StockNews.com.
View the latest analyst ratings for EVOK.

What is the current price target for Evoke Pharma?

0 Wall Street analysts have set twelve-month price targets for Evoke Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Evoke Pharma in the next year.
View the latest price targets for EVOK.

What is the current consensus analyst rating for Evoke Pharma?

Evoke Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EVOK.

What other companies compete with Evoke Pharma?

Other companies that are similar to Evoke Pharma include DURECT, KALA BIO, Daré Bioscience, Forte Biosciences and Longeveron. Learn More about companies similar to Evoke Pharma.

How do I contact Evoke Pharma's investor relations team?

Evoke Pharma's physical mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company's listed phone number is (858) 345-1494 and its investor relations email address is [email protected]. The official website for Evoke Pharma is www.evokepharma.com. Learn More about contacing Evoke Pharma investor relations.